Hubbry Logo
ArrestinArrestinMain
Open search
Arrestin
Community hub
Arrestin
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Arrestin
Arrestin
Arrestin
View on Wikipedia
from Wikipedia
S-antigen; retina and pineal gland (arrestin)
Crystallographic structure of the bovine arrestin-S.[1]
Identifiers
SymbolSAG
Alt. symbolsarrestin-1
NCBI gene6295
HGNC10521
OMIM181031
RefSeqNM_000541
UniProtP10523
Other data
LocusChr. 2 q37.1
Search for
StructuresSwiss-model
DomainsInterPro
arrestin beta 1
Identifiers
SymbolARRB1
Alt. symbolsARR1, arrestin-2
NCBI gene408
HGNC711
OMIM107940
RefSeqNM_004041
UniProtP49407
Other data
LocusChr. 11 q13
Search for
StructuresSwiss-model
DomainsInterPro
arrestin beta 2
Identifiers
SymbolARRB2
Alt. symbolsARR2, arrestin-3
NCBI gene409
HGNC712
OMIM107941
RefSeqNM_004313
UniProtP32121
Other data
LocusChr. 17 p13
Search for
StructuresSwiss-model
DomainsInterPro
arrestin 3, retinal (X-arrestin)
Identifiers
SymbolARR3
Alt. symbolsARRX, arrestin-4
NCBI gene407
HGNC710
OMIM301770
RefSeqNM_004312
UniProtP36575
Other data
LocusChr. X q
Search for
StructuresSwiss-model
DomainsInterPro

Arrestins (abbreviated Arr) are a small family of proteins important for regulating signal transduction at G protein-coupled receptors.[2][3] Arrestins were first discovered in the late '80s as a part of a conserved two-step mechanism for regulating the activity of G protein-coupled receptors (GPCRs) in the visual rhodopsin system by Hermann Kühn, Scott Hall, and Ursula Wilden[4] and in the β-adrenergic system by Martin J. Lohse and co-workers.[5][6]

Function

[edit]

In response to a stimulus, GPCRs activate heterotrimeric G proteins. In order to turn off this response, or adapt to a persistent stimulus, active receptors need to be desensitized. The first step in desensitization is phosphorylation of the receptor by a class of serine/threonine kinases called G protein coupled receptor kinases (GRKs). GRK phosphorylation specifically prepares the activated receptor for arrestin binding. Arrestin binding to the receptor blocks further G protein-mediated signaling and targets receptors for internalization, and redirects signaling to alternative G protein-independent pathways, such as β-arrestin signaling.[7][8][9][10][6] In addition to GPCRs, arrestins bind to other classes of cell surface receptors and a variety of other signaling proteins.[11]

Subtypes

[edit]

Mammals express four arrestin subtypes and each arrestin subtype is known by multiple aliases. The systematic arrestin name (1–4) plus the most widely used aliases for each arrestin subtype are listed in bold below:

  • Arrestin-1 was originally identified as the S-antigen (SAG) causing uveitis (autoimmune eye disease), then independently described as a 48 kDa protein that binds light-activated phosphorylated rhodopsin before it became clear that both are one and the same. It was later renamed visual arrestin, but when another cone-specific visual subtype was cloned the term rod arrestin was coined. This also turned out to be a misnomer: arrestin-1 expresses at comparable very high levels in both rod and cone photoreceptor cells.
  • Arrestin-2 was the first non-visual arrestin cloned. It was first named β-arrestin simply because of the two GPCRs available in purified form at the time, rhodopsin and β2-adrenergic receptor, it showed preference for the latter.
  • Arrestin-3. The second non-visual arrestin cloned was first termed β-arrestin-2 (retroactively changing the name of β-arrestin into β-arrestin-1), even though by that time it was clear that non-visual arrestins interact with hundreds of different GPCRs, not just with β2-adrenergic receptor. Systematic names, arrestin-2 and arrestin-3, respectively, were proposed soon after that.
  • Arrestin-4 was cloned by two groups and termed cone arrestin, after photoreceptor type that expresses it, and X-arrestin, after the chromosome where its gene resides. In the HUGO database its gene is called arrestin-3.

Fish and other vertebrates appear to have only three arrestins: no equivalent of arrestin-2, which is the most abundant non-visual subtype in mammals, was cloned so far. The proto-chordate Ciona intestinalis (sea squirt) has only one arrestin, which serves as visual in its mobile larva with highly developed eyes, and becomes generic non-visual in the blind sessile adult. Conserved positions of multiple introns in its gene and those of our arrestin subtypes suggest that they all evolved from this ancestral arrestin.[12] Lower invertebrates, such as roundworm Caenorhabditis elegans, also have only one arrestin. Insects have arr1 and arr2, originally termed visual arrestins because they are expressed in photoreceptors, and one non-visual subtype (kurtz in Drosophila). Later arr1 and arr2 were found to play an important role in olfactory neurons and renamed sensory. Fungi have distant arrestin relatives involved in pH sensing.

Tissue distribution

[edit]

One or more arrestin is expressed in virtually every eukaryotic cell. In mammals, arrestin-1 and arrestin-4 are largely confined to photoreceptors, whereas arrestin-2 and arrestin-3 are ubiquitous. Neurons have the highest expression level of both non-visual subtypes. In neuronal precursors both are expressed at comparable levels, whereas in mature neurons arrestin-2 is present at 10–20 fold higher levels than arrestin-3.[citation needed]

Mechanism

[edit]

Arrestins block GPCR coupling to G proteins in two ways. First, arrestin binding to the cytoplasmic face of the receptor occludes the binding site for heterotrimeric G-protein, preventing its activation (desensitization).[13] Second, arrestin links the receptor to elements of the internalization machinery, clathrin and clathrin adaptor AP2, which promotes receptor internalization via coated pits and subsequent transport to internal compartments, called endosomes. Subsequently, the receptor could be either directed to degradation compartments (lysosomes) or recycled back to the plasma membrane where it can again signal. The strength of arrestin-receptor interaction plays a role in this choice: tighter complexes tend to increase the probability of receptor degradation (Class B), whereas more transient complexes favor recycling (Class A), although this rule is far from absolute.[2] More recently direct interactions between Gi/o family G proteins and Arrestin were discovered downstream of multiple receptors, regardless of canonical G protein coupling.[14] These recent findings introduce a GPCR signaling mechanism distinct from canonical G protein activation and β-arrestin desensitization in which GPCRs cause the formation of Gαi:β-arrestin signaling complexes.

Structure

[edit]

Arrestins are elongated molecules, in which several intra-molecular interactions hold the relative orientation of the two domains. Unstimulated cell arrestins are localized in the cytoplasm in a basal inactive conformation. Active phosphorylated GPCRs recruit arrestin to the plasma membrane. Receptor binding induces a global conformational change that involves the movement of the two arrestin domains and the release of its C-terminal tail that contains clathrin and AP2 binding sites. Increased accessibility of these sites in receptor-bound arrestin targets the arrestin-receptor complex to the coated pit. Arrestins also bind microtubules (part of the cellular skeleton), where they assume yet another conformation, different from both free and receptor-bound form. Microtubule-bound arrestins recruit certain proteins to the cytoskeleton, which affects their activity and/or redirects it to microtubule-associated proteins.

Arrestins shuttle between cell nucleus and cytoplasm. Their nuclear functions are not fully understood, but it was shown that all four mammalian arrestin subtypes remove some of their partners, such as protein kinase JNK3 or the ubiquitin ligase Mdm2, from the nucleus. Arrestins also modify gene expression by enhancing transcription of certain genes.

Application

[edit]

S-Arrestin is a protein found in mice that binds to rhodopsin to stop its activity, preventing further signaling. S-arrestin binds to G protein-coupled receptors (GPCRs), like rhodopsin, following receptor activation and phosphorylation by G protein-coupled receptor kinases (GRKs). Rhodopsin is found in rod cells of the retina, essential for vision. It detects light and initiates a signaling cascade called phototransduction. However, excessive activation can be harmful, so it must be carefully regulated. The phosphorylation of the receptor's intracellular loops and C-terminal tail creates a high-affinity binding site for S-arrestin. S-arrestin then sterically hinders further G protein coupling, effectively desensitizing the receptor and directing it towards alternative signaling pathways or internalization via clathrin-mediated endocytosis.

Binding to rhodopsin

[edit]

The binding of S-arrestin to rhodopsin is specific and involves changes that occur in rhodopsin after activation. Important serine (Ser) and threonine (Thr) residues in rhodopsin's tail, particularly Thr-340 and Ser-343, are phosphorylated by enzymes called GRKs. These phosphorylated residues strongly attract S-arrestin, helping it bind tightly and effectively shut down rhodopsin's signaling.[15]

Additionally, studies of the protein structure have shown that during activation, rhodopsin's transmembrane helix 7 (TM7) and helix 8 change shape. These changes expose a binding site that interacts with a specific part of arrestin called the "finger loop." This interaction, clearly seen in the crystal structure (PDB ID: 4ZWJ), shows how arrestin fits precisely onto activated and phosphorylated rhodopsin, efficiently stopping the visual signal.[16]

Crystal structure showing where arrestin will precisely bound to activated and phosphorylated rhodopsin at key residues
Arrestin (or S-antigen), N-terminal domain
Structure of arrestin from bovine rod outer segments.[1]
Identifiers
SymbolArrestin_N
PfamPF00339
Pfam clanCL0135
InterProIPR011021
PROSITEPDOC00267
SCOP21cf1 / SCOPe / SUPFAM
Available protein structures:
Pfam  structures / ECOD  
PDBRCSB PDB; PDBe; PDBj
PDBsumstructure summary
PDB1ayr​ , 1cf1 ​ , 1g4m​ , 1g4r​ , 1jsy ​ , 1zsh​
Arrestin (or S-antigen), C-terminal domain
Structure of bovine beta-arrestin.[17]
Identifiers
SymbolArrestin_C
PfamPF02752
Pfam clanCL0135
InterProIPR011022
SCOP21cf1 / SCOPe / SUPFAM
Available protein structures:
Pfam  structures / ECOD  
PDBRCSB PDB; PDBe; PDBj
PDBsumstructure summary
PDB1ayr​ , 1cf1​ , 1g4m​ , 1g4r​ , 1jsy​ , 1suj​ , 1zsh​

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Arrestin

View on Grokipedia
from Grokipedia
Arrestins are a small family of regulatory proteins that modulate the signaling and trafficking of G protein-coupled receptors (GPCRs), the largest class of cell surface receptors in mammals, by binding to activated and phosphorylated forms of these receptors to terminate G protein-mediated signaling, promote receptor internalization, and scaffold alternative signaling pathways. In vertebrates, the arrestin family consists of four members: two visual arrestins, arrestin-1 (also known as S-antigen or rod arrestin) and arrestin-4 (cone arrestin), which are primarily expressed in photoreceptor cells to regulate phototransduction; and two non-visual β-arrestins, arrestin-2 (β-arrestin-1) and arrestin-3 (β-arrestin-2), which are ubiquitously expressed and interact with hundreds of GPCRs across various tissues. These proteins lack enzymatic activity and function solely as scaffolds, organizing multi-protein complexes by simultaneously binding receptors and downstream effectors on their structurally distinct surfaces. The discovery of arrestins began with the identification of visual arrestin-1 in the late 1970s as a major component of photoreceptors, initially termed the " S " for its role in quenching light-activated signaling in the . Subsequent in the 1980s and 1990s revealed the non-visual β-arrestins and extended their regulatory mechanisms to non-sensory GPCRs, establishing a paradigm for homologous desensitization where GPCR kinases (GRKs) phosphorylate activated receptors, enabling arrestin recruitment. Structurally, arrestins feature two globular domains—an N-terminal domain and a C-terminal domain—connected by a , with the containing motifs for binding endocytic machinery like and AP-2 adaptors, allowing them to redirect GPCRs from the plasma membrane to intracellular compartments. Beyond desensitization and , arrestins mediate biased agonism by selectively activating G protein-independent pathways, such as (MAPK) cascades, Src signaling, and even non-GPCR interactions like those with ion channels or nuclear transcription factors, influencing processes from to . Physiologically, arrestins are implicated in diverse functions, including sensory adaptation, immune responses, metabolism, and central nervous system signaling, with dysregulation linked to such as Oguchi disease (from arrestin-1 mutations), cancer progression, and neurodegenerative disorders like Alzheimer's and Parkinson's. Their multifaceted roles have positioned arrestins as key therapeutic targets, particularly for developing biased ligands that favor beneficial signaling while minimizing adverse effects in conditions like and . Recent advances as of 2025 include small-molecule enhancers of arrestin binding and detailed structural studies of GPCR-arrestin complexes, further supporting their role as drug targets.

Discovery and Nomenclature

Historical Background

The soluble protein known as S-antigen was first isolated from bovine extracts in 1977 by Wacker and colleagues, who identified it as a key capable of inducing experimental allergic in animal models. In the early , Hermann Kühn and his team began elucidating its functional role in phototransduction, demonstrating that this 48-kDa protein bound to light-activated and contributed to quenching the photoreceptor response. By the early , further studies by Kühn's group confirmed that the S-antigen, now recognized as the 48-kDa regulatory protein, specifically bound to phosphorylated and light-activated , thereby terminating the phototransduction cascade in rod outer segments. Advancements in the solidified arrestin's role as a regulator of , with Wilden, Hall, and Kühn reporting in 1986 that its binding to phosphorylated fully quenched activation, linking it mechanistically to (GPCR) desensitization. That same year, the functional importance of this interaction was underscored through affinity purification methods exploiting the light-dependent binding of the 48-kDa protein to phosphorylated . The first of the visual arrestin (SAG) occurred shortly thereafter in 1987, when Shinohara et al. sequenced the bovine cDNA, revealing its complete and enabling molecular studies of its expression. The 1990s marked the expansion of arrestin research beyond vision, with Robert Lefkowitz's laboratory cloning the non-visual β-arrestin-1 (arrestin-2) from a bovine cDNA library in 1990, using visual arrestin sequences as probes; these proteins were shown to desensitize β-adrenergic receptors and other non-visual GPCRs, followed by the cloning of β-arrestin-2 (arrestin-3) in 1992. This discovery established β-arrestins as ubiquitous regulators of GPCR signaling across tissues. Initial structural studies commenced around 1992, with Franke et al. using chemical modification and to probe arrestin's conformational properties, laying groundwork for understanding its molecular architecture. In the 2000s, research revealed arrestins' functional diversification beyond desensitization, including roles in receptor internalization, trafficking, and novel signaling pathways such as β-arrestin-mediated activation of MAPK cascades, as demonstrated in seminal work by Lefkowitz and colleagues on GPCR-β-arrestin scaffolds.

Naming Conventions

The visual arrestin was initially termed "S-antigen" in the due to its identification as a soluble antigen capable of inducing experimental autoimmune uveoretinitis in animal models. Independently, it was described as the "48 kDa protein" based on its approximate molecular weight and its specific binding to light-activated, phosphorylated in rod photoreceptors. The unified term "arrestin" was first proposed in 1986 to reflect the protein's function in halting ("arresting") the light-dependent activation of downstream of signaling. This nomenclature gained broader acceptance in the early 1990s following the cloning of non-visual homologs, with the first such protein designated β-arrestin in 1990 owing to its preferential interaction with the phosphorylated β2-adrenergic receptor over . Mammalian subtypes are systematically designated as arrestin-1 (also known as visual arrestin or S-arrestin), arrestin-2 (β-arrestin-1), arrestin-3 (β-arrestin-2), and arrestin-4 (cone arrestin or X-arrestin), reflecting their order of discovery and functional specialization. The Human Genome Organisation (HUGO) Gene Nomenclature Committee standardizes gene symbols as SAG for arrestin-1, ARRB1 for arrestin-2, ARRB2 for arrestin-3, and ARR3 for arrestin-4, ensuring consistency across genomic databases and literature. Early research generated terminological confusion, as visual arrestins were distinguished from ubiquitous non-visual forms, leading to overlapping synonyms like "retinal S-antigen" versus "β-arrestin." A consensus in the literature recommended the numerical system (arrestin-1 through -4) based on phylogenetic analysis and cloning chronology to eliminate ambiguity and facilitate cross-study comparisons. In non-mammalian organisms, particularly invertebrates such as , arrestins retain functional analogies but employ species-specific designations, with visual forms often labeled as retina-specific arrestins (e.g., Arr1 and Arr2 in photoreceptors) to highlight their localization in compound eyes.

Structure

Molecular Architecture

Arrestin proteins exhibit an elongated, concave overall shape characterized by a two-domain , consisting of an N-terminal domain and a C-terminal domain connected by a flexible region. This bipartite structure, with each domain comprising a bundle of antiparallel β-sheets, enables the protein to adopt a compact conformation in its basal state. Visual arrestin-1 (ARR1), a prototypical member, has a molecular weight of approximately 45-48 kDa. The N-terminal domain features a series of β-strands that form the primary interface for binding to activated G protein-coupled receptors (GPCRs), including a prominent finger loop (typically residues 68-78 in bovine ARR1, or approximately 70-80 across subtypes) that inserts into the receptor's intracellular core upon activation. The C-terminal domain, similarly structured with β-sheets, houses regulatory elements such as the clathrin-binding box motif (e.g., the LφXφ[D/E] , including variants like LLVDL in non-visual arrestins) that facilitates interactions with endocytic machinery. A polar core, composed of salt bridges and hydrogen bonds between conserved charged residues (e.g., Asp30, Arg175, Asp296, Asp303, and Arg382 in bovine ARR1), spans the interdomain interface and stabilizes the inactive conformation by restricting hinge flexibility. The first high-resolution of arrestin was that of bovine visual arrestin-1 in its basal state (PDB: 1CF1), determined at 2.8 resolution in 1999, revealing the conserved β-sandwich and the polar core's role in maintaining inactivity. Subsequent structures of other subtypes, such as arrestin-3 (PDB: 3P2D), confirm these common features, including the finger loop's positioning for receptor engagement across the family. Post-translational modifications, particularly , occur predominantly on the C-terminal tail and influence arrestin activation. In visual arrestin-1, C-terminal sites such as Thr368 and Ser369 are phosphorylated in a light-dependent manner by or , modulating the tail's interaction with the N-domain and facilitating release upon receptor binding. Similar phosphorylation patterns in non-visual arrestins (e.g., Ser412 in β-arrestin-1 by GRK5) fine-tune conformational accessibility.

Conformational Dynamics

Arrestins adopt a basal inactive conformation characterized by intramolecular constraints that prevent premature binding to G protein-coupled receptors (GPCRs). A key stabilizing element is the polar core, a network of charged residues spanning the N- and C-domains as well as the C-terminal tail, forming salt bridges and hydrogen bonds that latch the tail in place. For instance, in visual arrestin (arrestin-1), residues such as Asp30, Arg175, Asp296, Asp303, and Arg382 contribute to this core, maintaining a compact structure and occluding receptor-interacting surfaces like the finger loop. Similarly, in β-arrestin-1, the polar core involves Asp26, Arg169, Asp290, Asp297, and Arg393, ensuring the protein remains inactive until stimulated. Activation begins with GPCR phosphorylation by G protein-coupled receptor kinases (GRKs), which introduces negative charges on the receptor's C-tail. These phosphates engage the arrestin's polar core, displacing the C-terminal latch and releasing the finger loop (residues 67–79 in β-arrestin-1) to insert into the activated receptor's intracellular core, primarily interacting with transmembrane helices 6 and 7. This propagates conformational changes, including an approximately 20° twist at the inter-domain hinge connecting the N- and C-domains, which separates the domains and stabilizes the active state. The tail displacement further exposes cryptic binding sites on the C-domain for endocytic proteins like and AP-2. Recent cryo-EM structures of arrestin-GPCR complexes (as of 2020) confirm this interdomain twist and reveal subtype-specific variations in . In the active conformation, arrestins exhibit enhanced flexibility, with the domains adopting an open arrangement that facilitates downstream interactions. (NMR) studies since 2010 have illuminated intermediate states during this transition, revealing dynamic rearrangements in the finger loop and polar core prior to full activation; for example, 19F NMR on β-arrestin-1 showed distinct phospho-dependent conformational shifts induced by receptor peptides or lipids like PIP2. Additionally, at Ser-412 in β-arrestin-1 modulates its nuclear shuttling, enabling translocation to regulate independently of GPCRs. Subtype-specific differences influence these dynamics: visual arrestins (arrestin-1 and -4) are relatively rigid, optimized for rapid desensitization in photoreceptors, whereas non-visual β-arrestins (arrestin-2 and -3) display greater conformational flexibility in their C-tails and loops, allowing adoption of multiple active poses for diverse signaling scaffolds beyond desensitization. Hydrogen-deuterium exchange has quantified this, showing β-arrestin-1 mutants with altered polar cores exhibit broader dynamic ranges compared to their visual counterparts.

Subtypes and Evolution

Mammalian Arrestins

In mammals, four distinct arrestin subtypes have been identified, each encoded by a specific and exhibiting unique tissue specificity and functional properties tailored to (GPCR) regulation. These subtypes include two visual arrestins primarily expressed in photoreceptors and two non-visual β-arrestins that are more broadly distributed and interact with a wide array of GPCRs. Arrestin-1, also known as visual arrestin or S-antigen, is encoded by the SAG gene located on chromosome 2q37.1 and consists of approximately 404 amino acids. It is specifically expressed in rod and photoreceptors of the , where it demonstrates high affinity binding to light-activated, phosphorylated , thereby facilitating the rapid quenching of phototransduction signals to prevent prolonged activation. Arrestin-2, commonly referred to as β-arrestin-1, is encoded by the ARRB1 gene on chromosome 11q13.4. This subtype is ubiquitously expressed across various tissues and interacts with numerous GPCRs, contributing to receptor desensitization and internalization; it features a shorter C-terminal tail compared to arrestin-3, which influences its binding dynamics and conformational flexibility. Arrestin-3, or β-arrestin-2, is encoded by the ARRB2 gene situated on chromosome 17p13.2 and is also ubiquitously expressed, but it exhibits broader specificity toward diverse GPCRs than arrestin-2. Notably, it serves as a key scaffold for the ERK/MAPK signaling pathway, facilitating the assembly of complexes downstream of activated receptors to modulate cellular responses such as proliferation and migration. Arrestin-4, known as cone arrestin, is encoded by the ARR3 on chromosome Xq13.1. It is cone photoreceptor-specific and shares structural similarities with arrestin-1, including a comparable domain organization, but displays lower affinity for , allowing for more transient interactions suited to cone phototransduction dynamics. Mutations in ARR3 have been linked to X-linked female-limited early-onset high .

Non-Mammalian Variants

Arrestins in exhibit specialized adaptations tailored to sensory signaling, differing from the more diversified mammalian forms. In , the primary visual arrestin, Arr2, plays a central role in terminating phototransduction by binding to phosphorylated in photoreceptor cells, preventing prolonged activation of the visual cascade. This species lacks canonical β-arrestin homologs typically involved in non-visual GPCR regulation in mammals, with Arr2 serving as the dominant effector for light response deactivation. Similarly, in the nematode , the sole arrestin ortholog, ARR-1, functions in desensitizing chemosensory G protein-coupled receptors (GPCRs), facilitating olfactory adaptation and recovery to volatile odorants by promoting receptor and signal termination. These arrestins highlight an ancestral focus on sensory-specific roles, without the subtype specialization seen in higher organisms. The evolution of arrestins in s involved key events approximately 500 million years ago (MYA), coinciding with two rounds of whole-genome duplication in the vertebrate stem lineage. These events generated four paralogs: visual arrestins (arrestin-1 and arrestin-4) and non-visual arrestins (arrestin-2 and arrestin-3), enabling partitioned functions in phototransduction and broader GPCR signaling. In teleost fish, which underwent an additional genome duplication, multiple arrestin paralogs remain functional, including those contributing to cone-mediated vision. ARR3 is conserved and functional across s, including mammals and sauropsids. Functional adaptations in non-mammalian arrestins underscore environmental influences on binding dynamics. In amphibians, such as frogs and salamanders, visual arrestin-1 exhibits temperature-sensitive binding to phosphorylated , with affinity and translocation rates varying markedly across physiological temperature ranges to optimize phototransduction in ectothermic conditions. In plants like , arrestin-like proteins, including VPS26 components of the retromer complex, adopt β-arrestin-like roles in regulating non-GPCR signaling pathways, such as those involving the seven-transmembrane regulator AtRGS1, which modulates light-responsive processes akin to phototropin-mediated responses without direct GPCR involvement. Phylogenetically, the arrestin family diverged from α-arrestins, which function as cargo adapters in endosomal sorting, around 1 billion years ago (BYA), near the emergence of eukaryotic multicellularity. This ancient split predates the metazoan-specific expansions of visual and β-arrestins, with α-arrestins conserved across and animals for non-desensitization roles. In comparison to mammalian subtypes, which feature four active paralogs with refined GPCR interactions, non-mammalian variants emphasize broader evolutionary conservation in sensory and trafficking contexts.

Expression and Tissue Distribution

Patterns of Expression

Arrestin-1 and arrestin-4, the visual subtypes, are primarily expressed in photoreceptor cells, with arrestin-1 predominantly in rod photoreceptors and arrestin-4 in cone photoreceptors. In rods, arrestin-1 is the second most abundant protein, expressed at a molar ratio of approximately 0.8:1 relative to and reaching concentrations exceeding 100 μM. These proteins are also present in pinealocytes, though at lower levels than in the . In contrast, the non-visual arrestins, arrestin-2 and arrestin-3 (also known as β-arrestin-1 and β-arrestin-2), exhibit broad expression across virtually all mammalian cell types and tissues. Their highest levels occur in the , particularly in neurons, where arrestin-2 predominates at concentrations around 200 nM compared to about 10 nM for arrestin-3, resulting in a 10- to 20-fold excess of arrestin-2. Elevated expression is also noted in the and leukocytes, including lymphocytes, while levels remain low in the liver and . Within cells, arrestins reside primarily in the in their inactive state but translocate to the plasma membrane upon activation of G protein-coupled receptors (GPCRs). In certain cell types, such as neurons, arrestins can additionally localize to the nucleus, with their export mediated by the CRM1 exportin. Developmentally, arrestin-1 expression increases during retinal maturation, aligning with the differentiation of photoreceptors in postnatal stages. Meanwhile, β-arrestins maintain constitutive expression in most tissues following embryogenesis, with presence detectable as early as in neural precursors.

Regulation of Expression

The expression of arrestin genes is tightly regulated at multiple levels to ensure appropriate protein levels in response to cellular needs. Transcriptional control plays a central role, particularly for visual arrestin (SAG), whose promoter is responsive to retinal-specific transcription factors such as cone-rod (CRX) and neural retina (NRL). These factors bind to cis-regulatory elements in the SAG promoter, driving its expression in photoreceptor cells to maintain phototransduction efficiency. For non-visual arrestins, β-arrestin-1 (ARRB1) expression is directly upregulated by nuclear factor kappa B () during conditions, forming a feedback loop where binds to the ARRB1 promoter to enhance transcription and modulate immune responses. Similar regulation occurs for β-arrestin-2 (ARRB2), though to a lesser extent, contributing to resolution. Post-transcriptional mechanisms further fine-tune arrestin levels. MicroRNAs, such as miR-155, target the 3' untranslated region of ARRB2 mRNA, leading to its downregulation in immune cells like macrophages during or inflammatory states, thereby altering GPCR signaling in adaptive immunity. of ARRB1 transcripts is relatively rare but generates distinct isoforms, including a variant lacking 13 that influences protein function and tissue-specific expression patterns in the and peripheral tissues. These spliced forms arise from tissue-dependent regulation, potentially modulating β-arrestin-1's role in receptor trafficking. Protein stability is another key regulatory layer, primarily governed by ubiquitination. The E3 MDM2 mediates the polyubiquitination of β-arrestins, targeting them for proteasomal degradation and controlling their turnover in GPCR signaling complexes. For instance, β-arrestin-2 exhibits a of approximately 10-12 hours in mammalian cells, which can be extended or shortened based on receptor and ubiquitination status. This dynamic degradation ensures transient arrestin function during signaling events. Pathological alterations in arrestin expression contribute to disease progression. In , mutations in the SAG gene often result in functional downregulation or loss of arrestin-1 protein, leading to impaired deactivation and photoreceptor degeneration, as observed in dominant forms prevalent in certain populations. Conversely, post-2000 studies have documented upregulation of β-arrestins in models, where increased ARRB1 and ARRB2 levels in cardiac fibroblasts promote maladaptive remodeling and in response to chronic β-adrenergic stimulation.

Functions

Desensitization of GPCRs

Arrestins play a central role in the desensitization of s (GPCRs) by terminating -mediated signaling through a phosphorylation-dependent mechanism. Upon activation, GPCRs undergo primarily by G protein-coupled receptor kinases (GRKs) on their intracellular loops and C-terminal tail, creating a high-affinity for arrestins. The binding of arrestin to the phosphorylated, activated GPCR sterically occludes the G protein interaction site on the receptor, thereby preventing further G protein coupling and . This process ensures rapid uncoupling of the receptor from its downstream effectors, maintaining cellular and preventing overstimulation. The desensitization process is notably rapid, occurring on the order of seconds for most non-visual GPCRs, which allows for quick adaptation to sustained exposure. In the , arrestin-1 quenches the photoactivated signal with sub-second kinetics, typically within less than 100 ms, to enable high in phototransduction and prevent prolonged that could lead to saturation. This swift termination is critical for single-photon detection in rod photoreceptors, where incomplete desensitization would result in extended signaling and impaired visual recovery. Different arrestin subtypes exhibit specialized roles in GPCR desensitization. Arrestin-1 is highly selective for opsins, such as in rod cells, where it binds exclusively to the light-activated, phosphorylated form to block coupling with exceptional specificity. In contrast, the non-visual β-arrestins (β-arrestin-1 and β-arrestin-2) interact with a broad range of class A and class B GPCRs, including adrenergic, , and receptors, facilitating desensitization across diverse physiological contexts like cardiovascular regulation and immune responses. Phosphorylation dramatically enhances arrestin binding affinity, often by 10- to 100-fold depending on the receptor and pattern, transforming low-affinity interactions with the active receptor core into stable complexes that effectively hinder access. This affinity shift is mediated by electrostatic interactions between arrestin phosphate-binding elements and the receptor's phosphorylated residues, ensuring selective engagement only with activated states. Failure to achieve complete desensitization, such as due to insufficient or arrestin availability, can lead to sustained signaling, contributing to pathological conditions like receptor hypersensitivity.

Internalization and Trafficking

β-Arrestins play a central role in the clathrin-mediated endocytosis of activated G protein-coupled receptors (GPCRs) by serving as adaptor proteins that link phosphorylated receptors to the endocytic machinery. Upon agonist-induced activation and subsequent phosphorylation by G protein-coupled receptor kinases (GRKs), β-arrestins (specifically arrestin-2 and arrestin-3) bind to the receptor's C-terminal tail, sterically blocking further G protein coupling while recruiting the adaptor protein complex AP-2 and clathrin heavy chains. This recruitment occurs through specific motifs in the C-terminal tail of β-arrestins, such as the clathrin-binding box exemplified by the LΦEΦ(D/E) sequence (where Φ represents a bulky hydrophobic residue), which interacts with the N-terminal β-propeller domain of clathrin, and a separate site for AP-2 binding via the β2-adaptin subunit. The resulting complex facilitates the formation of clathrin-coated pits at the plasma membrane, with dynamin GTPases mediating the pinching off of coated vesicles to internalize the receptor-arrestin complex. Following endocytosis, the GPCR-β-arrestin complexes are trafficked to early endosomes, where the receptors are sorted into distinct pathways that determine their fate: recycling back to the plasma membrane or lysosomal degradation. In early endosomes, Rab4 and Rab11 GTPases promote rapid recycling of dephosphorylated receptors to the cell surface, restoring responsiveness, while Rab7 directs receptors toward late endosomes and lysosomes for ubiquitination-dependent degradation. The stability of the β-arrestin-receptor interaction influences this sorting; transient binding, often mediated by arrestin-2, favors recycling, whereas more stable complexes, particularly those involving arrestin-3, bias certain GPCRs (such as protease-activated receptor 2) toward degradation by facilitating ubiquitination and association with the endosomal sorting complex required for transport (ESCRT) machinery. The process of internalization is rapid, with maximal receptor uptake typically occurring 2-5 minutes after agonist stimulation, as observed in studies of prototypical GPCRs like the β2-adrenergic receptor. In endosomes, protein phosphatase 2A (PP2A), which associates with β-arrestin, the receptor, leading to dissociation of the arrestin complex and enabling either recycling or further trafficking. This step is crucial for terminating arrestin-mediated processes and resensitizing the receptor. Beyond GPCRs, β-arrestins (arrestin-2 and arrestin-3) also mediate the of non-GPCR receptors, expanding their role in receptor trafficking. For instance, β-arrestin-2 interacts with the type III transforming growth factor-β (TGF-β) receptor, promoting its clathrin-dependent internalization and subsequent downregulation of TGF-β signaling, thereby regulating pathways involved in cell growth and .

Scaffold for Signaling

β-Arrestins function as scaffolds that assemble multi-protein signaling complexes, facilitating (GPCR)-mediated pathways independent of heterotrimeric G proteins. For instance, β-arrestin-3 recruits components of the (MAPK) cascade, including ERK1/2, MEK, and Raf, to promote their sequential activation downstream of activated GPCRs. This scaffolding biases signaling toward G protein-independent routes, enabling distinct cellular responses such as proliferation and migration. A prominent example is the of the MAPK/ERK pathway within endosomes following GPCR internalization. Upon , β-arrestins facilitate the translocation of receptor-arrestin complexes to endosomes, where ERK1/2 occurs and persists for 30-60 minutes, in contrast to the transient seconds-long at the plasma membrane via pathways. β-Arrestin-2 similarly scaffolds the PI3K/Akt pathway, forming complexes that enhance Akt and promote cell signals, as observed in dopamine D2 receptor . Arrestin-3 exhibits a stronger preference for ERK scaffolding compared to arrestin-2, due to higher binding affinity to ERK2 via distinct molecular interfaces. Recent structural studies as of 2025 have revealed noncanonical Gαi:β-arrestin heterotrimers that sustain signaling from internalized GPCRs, integrating and arrestin functions for prolonged ERK , along with versatile stoichiometries (e.g., 2:1 and 2:2) that enable biased signaling outcomes. In immune contexts, β-arrestins scaffold chemokine receptors like CXCR4 to modulate ERK and JNK pathways, influencing leukocyte chemotaxis and inflammatory responses. Additionally, β-arrestin-2 undergoes nuclear translocation upon GPCR stimulation, where it interacts with NF-κB components to regulate target gene expression, such as those involved in inflammation and apoptosis.

Mechanisms of Action

Phosphorylation-Dependent Binding

Upon agonist binding to G protein-coupled receptors (GPCRs), GPCR kinases (GRKs), particularly GRK2 and GRK5 for β-arrestins, phosphorylate serine and threonine residues in clusters located primarily in the receptor's C-terminal tail and intracellular loop 3 (i3 loop). This phosphorylation event, which occurs rapidly following receptor activation, creates negatively charged phosphate groups that serve as a primary signal for arrestin recruitment, distinguishing activated from inactive receptor states. GRK-mediated phosphorylation is essential for high-affinity arrestin binding, as it neutralizes repulsive forces between the positively charged arrestin and the receptor core while providing specific docking sites for interaction. The binding interface between arrestins and phosphorylated GPCRs involves direct electrostatic interactions between the receptor's phosphate groups and specific arginine and aspartate residues in the arrestin's N-terminal domain, often referred to as the "phosphate sensor." In visual arrestin (arrestin-1), this sensor includes the between Arg175 and Asp296, which is disrupted by binding, allowing conformational release of the arrestin's C-tail and enabling receptor engagement. A two-step binding model governs this process: initial insertion of the receptor's phosphorylated C-tail into a groove on the arrestin's N-domain, followed by closure of the arrestin onto the receptor's transmembrane core for stable complex formation. Similar mechanisms apply to β-arrestins (arrestin-2 and -3), where conserved basic residues in the N-domain, such as Arg8, Lys10, and Lys11, coordinate , ensuring selectivity for GRK-phosphorylated sites. Affinity for arrestin binding is tightly modulated by . Visual arrestin requires both light-activated conformation and multiple phosphorylations (e.g., at Ser334, Ser338, Thr336) for high-affinity interaction, preventing premature binding in the dark. In contrast, β-arrestins can bind agonist-activated, non-phosphorylated GPCRs with moderate affinity (e.g., to β2-adrenergic receptor), but dramatically enhances stability, often by 100-fold or more, promoting desensitization and trafficking. This enhancement arises from the "code," where patterns like PxPxxP/E/D motifs in the C-tail optimally engage the arrestin sensor. Kinetic parameters of arrestin-GPCR binding reflect this phosphorylation dependence, with rapid association rates enabling quick upon GRK action. Dissociation half-lives vary by subtype and receptor, ranging from approximately 1 minute for transient β-arrestin complexes to 10 minutes or longer for visual arrestin-rhodopsin interactions, influenced by the number and position of phosphates. These kinetics ensure timely signal termination while allowing for downstream signaling scaffolds.

Interactions with Other Proteins

Arrestins, particularly β-arrestin-1 (arrestin-2) and β-arrestin-2 (arrestin-3), function as adaptor proteins that facilitate the recruitment of endocytic machinery to phosphorylated G protein-coupled receptors (GPCRs), enabling receptor internalization and trafficking. Beyond GPCRs, arrestins interact with through a conserved clathrin-binding motif, often denoted as the ΦxΦΦ (where Φ represents hydrophobic residues), located in the C-terminal of β-arrestins; this interaction promotes the formation of clathrin-coated pits during . Similarly, β-arrestins bind to the AP-2 adaptor complex via specific sites, including arginine residues such as Arg394 and Arg396 in their C-terminal domain, which facilitate the clustering of receptors into clathrin-coated pits and subsequent vesicular trafficking. For receptor degradation, arrestin-2 engages components of the endosomal sorting complex required for transport () machinery, particularly ESCRT-0 subunits like HRS and STAM-1, to direct ubiquitinated receptors toward lysosomes. In signaling contexts, arrestins serve as scaffolds for non-receptor s and enzymes. Arrestin-3 specifically activates c-Jun N-terminal 3 (JNK3) through a unique binding interface involving key residues in its C-loop and lariat loop, such as Lys-295, which positions JNK3 for by upstream MAP kinases like MKK4; this interaction is phosphorylation-independent and distinct from GPCR binding. Additionally, arrestin-2 binds 4 (PDE4) isoforms, particularly PDE4D5, via a site in the enzyme's upstream conserved region, leading to localized hydrolysis of cAMP and attenuation of signaling at the plasma membrane. Arrestins also partner with non-GPCR receptors to modulate diverse pathways. In the Wnt signaling cascade, β-arrestins interact with receptors to scaffold and other components, promoting β-catenin stabilization and transcriptional activation in a G protein-independent manner. For receptor tyrosine kinases, β-arrestin-1 associates with the insulin receptor substrate-1 (IRS-1) to inhibit its ubiquitination and degradation, thereby fine-tuning insulin signaling and , though direct binding to the itself remains context-dependent. Emerging evidence implicates arrestin-2 in viral entry processes, where it facilitates SARS-CoV-2 spike protein-mediated via interactions with ACE2 and endocytic adaptors, enhancing infectivity in host cells. Regulatory interactions further diversify arrestin functions. The E3 ubiquitin ligase binds β-arrestins in their inactive conformation, promoting arrestin ubiquitination on lysine residues in the ; this modification targets arrestins for degradation or alters their capacity during GPCR trafficking. Meanwhile, 14-3-3 proteins, such as the τ isoform, interact with phosphorylated β-arrestins to modulate their subcellular localization, including facilitation of nuclear via CRM1-dependent mechanisms, which prevents excessive nuclear accumulation and sustains cytoplasmic signaling roles. Recent structural studies (as of 2024) have revealed allosteric pre-activation of β-arrestin-2 by phosphoinositides like IP6 and PIP2, which stabilize conformational changes in the βXX strand and enhance GPCR binding dynamics. Additionally, small molecules that stabilize the pre-activated arrestin conformation have been identified, offering potential for modulating arrestin-dependent signaling pathways.

Specific Interactions

With Rhodopsin

Arrestin-1, also known as visual arrestin or S-arrestin, exhibits high selectivity for the light-activated, phosphorylated form of (P-Rh*), binding primarily to its C-terminal tail phosphorylated at key residues such as Thr340, Ser334, Ser338, and Ser343. These phosphorylation sites, introduced by (GRK1), create negatively charged motifs that engage positively charged regions on arrestin-1's N-domain, stabilizing the complex and preventing further G-protein () interaction.62457-9/fulltext) Upon light absorption, 's 11-cis-retinal isomerizes to all-trans-retinal, inducing a conformational change that exposes the phosphorylated and opens a crevice between transmembrane 6 and 7 (TM6/7). This allows arrestin-1's finger loop (residues 70-78) to insert as a short α- into the TM6/7 crevice, interacting with residues like N310 and Q312 on TM7 and 8, while the phosphorylated tail docks onto arrestin-1's phosphate-binding groove. The binding affinity is dramatically enhanced by , with a (Kd) of approximately 50 nM for P-Rh* compared to over 80 μM for dark phosphorylated rhodopsin (P-Rh), ensuring arrestin-1 binds only the signaling-competent state. This interaction rapidly quenches rhodopsin signaling by sterically blocking transducin binding, terminating activation within sub-second kinetics to support high temporal resolution in vision. Mutations impairing arrestin-1 binding, such as those associated with Oguchi disease (e.g., frameshift deletions in the SAG gene leading to truncated protein), prolong rhodopsin activity, resulting in stationary night blindness and Mizuo-Nakamura fundus. Structurally, arrestin-1's compact, less flexible conformation relative to β-arrestins enables precise, high-affinity engagement tailored for the rapid shutoff required in phototransduction, as revealed by cryo-EM and structures like PDB 4ZWJ (2015), which shows the core binding interface without the extensive domain rearrangements seen in non-visual arrestins.

With Other Receptors

Arrestins, particularly β-arrestin-2 and β-arrestin-3 (also known as arrestin-2 and arrestin-3), play a critical role in the desensitization of β2-adrenergic receptors (β2-ARs), a prototypical class of s (GPCRs). Upon stimulation, β2-ARs are phosphorylated by G protein-coupled receptor kinases (GRKs), enabling the recruitment of β-arrestins, which sterically hinder further coupling and promote receptor internalization. This process terminates β2-AR-mediated signaling, such as cAMP production via Gs proteins, and facilitates receptor trafficking to endosomes. Certain ligands exhibit biased agonism at β2-ARs, preferentially activating β-arrestin pathways over signaling. For instance, the β-blocker stabilizes a receptor conformation that uncouples β2-AR from Gs while enhancing β-arrestin recruitment and downstream signaling, such as ERK activation, contributing to its cardioprotective effects. This bias contrasts with traditional agonists like isoproterenol, which primarily engage s, highlighting arrestins' role in ligand-specific signaling outcomes at β2-ARs. In chemokine receptors, arrestin-3 specifically facilitates the internalization of , a key co-receptor. Agonist-induced of recruits arrestin-3, which scaffolds the receptor with endocytic machinery, including , to drive clathrin-mediated and prevent viral entry. Dominant-negative arrestin-3 mutants block this process, underscoring its essential scaffolding function in trafficking and desensitization to ligands like SDF-1α. Arrestin-2 mediates the degradation of the angiotensin II type 1 receptor (AT1R) following binding. Phosphorylated AT1R recruits arrestin-2, leading to and sorting into lysosomes for proteolytic degradation, which downregulates receptor density and attenuates II-induced signaling, such as . Receptor variants influence this pathway, with some promoting lysosomal targeting over recycling, thereby modulating sustained AT1R activity in cardiovascular contexts. Beyond GPCRs, arrestins interact with non-GPCR receptors to regulate trafficking and signaling. For the Notch receptor, β-arrestins cooperate with α-arrestin 1 (ARRDC1) to form heterodimers that promote and ubiquitination of non-activated Notch, facilitating its lysosomal degradation and fine-tuning developmental signaling. Similarly, at (PAR2), a GPCR-like receptor activated by proteases, enables β-arrestin binding, which uncouples PAR2 from G proteins and mediates proinflammatory ERK signaling while promoting internalization. Arrestin binding affinity and duration vary across GPCR classes, influencing signaling dynamics. Class A GPCRs, characterized by short C-terminal tails (e.g., β2-AR), exhibit transient β-arrestin interactions that primarily support desensitization and rapid recycling, with quick dissociation post-internalization. In contrast, class B GPCRs with longer tails (e.g., AT1R) form stable, sustained complexes that enable prolonged β-arrestin-mediated signaling from endosomes, such as MAPK activation, before eventual degradation or resensitization. This dichotomy underscores arrestins' versatility in tailoring GPCR responses to cellular contexts.

Applications and Research

In Visual Phototransduction

In , arrestin-1 (also known as S-arrestin or visual arrestin) plays a central role in terminating the signaling cascade in rod photoreceptors by binding to light-activated, phosphorylated (P-Rh*). This high-affinity interaction, with a of approximately 4 nM, sterically blocks further binding of to P-Rh*, thereby halting the exchange of GDP for GTP on and preventing activation of 6 (PDE6). As a result, PDE6 ceases to hydrolyze cyclic GMP (cGMP), allowing to replenish cGMP levels, which reopens cGMP-gated cation channels and restores the rod's dark current, enabling rapid recovery from light exposure. This quenching occurs within milliseconds, with arrestin-1 encountering at rates up to 50 times per second, ensuring precise signal termination essential for high-fidelity vision. Following signal decay, arrestin-1 dissociates from P-Rh*, permitting of by protein phosphatase 2A (PP2A), a process that facilitates regeneration and dark adaptation. In wild-type rods, this is largely complete within 1-2 hours of darkness, though full dark adaptation, including pigment regeneration, typically requires about 30 minutes for substantial recovery after moderate bleaches. Arrestin-1 actively facilitates this , as evidenced by persistent phosphorylation beyond 3 hours in arrestin-1 knockout mice, leading to delayed dark adaptation. in the SAG gene encoding arrestin-1, such as the common homozygous 1-bp deletion (1147delA), underlie Oguchi disease type 1, an autosomal recessive form of characterized by prolonged rod photoresponses and impaired night vision due to defective quenching. Similarly, arrestin-1 knockout mice exhibit markedly prolonged photoresponses, with recovery times extended by orders of magnitude, underscoring arrestin-1's indispensable role in signal shutoff. In photoreceptors, which mediate and require higher temporal resolution, arrestin-4 (cone arrestin) performs an analogous function by binding phosphorylated cone opsins (such as S- and M-opsins) to terminate their signaling. This binding occurs rapidly, within about 80 ms post-photoactivation, enabling faster inactivation kinetics—up to 70-fold quicker than in —compared to arrestin-1, which supports cones' ability to detect rapid changes in light intensity and color. Although arrestin-1 is coexpressed in cones at much higher levels and can partially compensate, arrestin-4 is specialized for cone-specific shutoff, as double knockout models show significantly slowed cone recovery tails exceeding 750 ms.

Therapeutic Implications

Arrestins have emerged as key therapeutic targets in various diseases due to their roles in (GPCR) signaling modulation. Biased ligands that preferentially activate β-arrestin pathways over signaling represent a promising for selective therapeutic intervention. For instance, TRV027, a β-arrestin-biased of the II type 1 receptor (AT1R), was developed to promote cardioprotective effects while minimizing in . In the phase IIb BLAST-AHF conducted in the 2010s, involving 621 patients with , intravenous TRV027 demonstrated dose-dependent blood pressure reduction and some improvements in dyspnea, though it did not meet the primary endpoint of enhanced clinical status at day 30 compared to . Gene therapy approaches leveraging arrestins have shown preclinical potential in retinal disorders. In models of retinitis pigmentosa (RP), adeno-associated virus (AAV)-mediated delivery of a modified arrestin-1 variant enhances glycolytic flux in rod photoreceptors by disinhibiting enolase-1, thereby increasing lactate production to support photoreceptor survival. This strategy protected retinal structure and function in RP mouse models, preserving electroretinogram responses and reducing photoreceptor degeneration over several months post-injection. In , modulating arrestin-2 (β-arrestin-1) expression via offers a means to overcome chemoresistance. siRNA-mediated knockdown of arrestin-2 in breast cancer cell lines, such as and MDA-MB-231, reduced X-linked inhibitor of apoptosis protein (XIAP) levels, thereby sensitizing cells to chemotherapeutic agents like and . This approach decreased cell viability by 30-50% in multidrug-resistant models and enhanced , highlighting arrestin-2's role in promoting resistance through anti-apoptotic signaling. Diagnostic and imaging applications of arrestins are advancing, particularly for visualizing GPCR-arrestin interactions. Post-2020 developments include β-arrestin-biased (PET) tracers, such as carbon-11-labeled ligands targeting the serotonin 2A receptor, which selectively bind active receptor conformations to monitor β-arrestin recruitment . These tracers exhibited favorable in rodent models, enabling quantification of biased signaling dynamics in cerebral tissues with high specificity. In 2024, the discovery of small-molecule inhibitors that selectively target β-arrestins was reported, delineating their through comprehensive biophysical and biochemical assays and offering a novel direct modulation strategy for arrestin functions in disease. Emerging therapeutic areas include their involvement in viral pathologies. In , β-arrestin-biased AT1R agonists like TRV027 have been proposed to counteract SARS-CoV-2-induced ACE2 downregulation, which exacerbates II-mediated and lung injury, based on 2021 preclinical studies showing reduced release and improved endothelial function.

References

  1. https://www.nature.com/articles/s12276-023-01144-4
  2. https://genomebiology.biomedcentral.com/articles/10.1186/gb-2006-7-9-236
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC10441628/
  4. https://www.mdpi.com/1422-0067/25/11/6284
  5. https://www.nature.com/articles/s42004-025-01581-4
  6. https://portlandpress.com/biochemsoctrans/article/52/6/2333/235226/Advances-in-the-molecular-understanding-of-GPCR
  7. https://pubmed.ncbi.nlm.nih.gov/6436059/
  8. https://pubmed.ncbi.nlm.nih.gov/2163110/
  9. https://pubmed.ncbi.nlm.nih.gov/1517224/
  10. https://doi.org/10.1016/0014-5793(86)80008-4
  11. https://www.science.org/doi/10.1126/science.2163110
  12. https://genenames.org/data/genegroup/#!/group/1312
  13. https://bmcecolevol.biomedcentral.com/articles/10.1186/1471-2148-8-222
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC11105767/
  15. https://febs.onlinelibrary.wiley.com/doi/10.1111/febs.15811
  16. https://www.sciencedirect.com/science/article/pii/S0959440X16301774
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC4625158/
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC3034793/
  19. https://www.pnas.org/doi/10.1073/pnas.96.11.6072
  20. https://www.nature.com/articles/srep15808
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC3654799/
  22. https://www.mdpi.com/1422-0067/18/12/2519
  23. https://www.nature.com/articles/s41586-020-2377-8
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC6294333/
  25. https://www.nature.com/articles/ncomms9202
  26. https://pubmed.ncbi.nlm.nih.gov/15520010/
  27. https://www.sciencedirect.com/science/article/abs/pii/S1047847715000787
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC5501109/
  29. https://www.ncbi.nlm.nih.gov/gene/6295
  30. https://omim.org/entry/181031
  31. https://www.uniprot.org/uniprotkb/P10523/entry
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC5455168/
  33. https://www.ncbi.nlm.nih.gov/gene/408
  34. https://www.uniprot.org/uniprotkb/P49407/entry
  35. https://www.ncbi.nlm.nih.gov/gene/409
  36. https://www.uniprot.org/uniprotkb/P32121/entry
  37. https://pubmed.ncbi.nlm.nih.gov/11090355/
  38. https://www.ncbi.nlm.nih.gov/gene/407
  39. https://omim.org/entry/301770
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC4544185/
  41. https://www.sciencedirect.com/science/article/abs/pii/S1047847725000085
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC10238396/
  43. https://www.science.org/doi/10.1126/scisignal.abe4090
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC3020241/
  45. https://www.ahajournals.org/doi/10.1161/01.res.81.6.1021
  46. https://www.sciencedirect.com/science/article/pii/S002192581937125X
  47. https://www.jbc.org/article/S0021-9258%2818%2936497-4/fulltext
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC4669854/
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC6391623/
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC1153713/
  51. https://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.201700642RRR
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC5564567/
  53. https://pubmed.ncbi.nlm.nih.gov/9767391/
  54. https://pubmed.ncbi.nlm.nih.gov/8486659/
  55. https://www.pnas.org/doi/10.1073/pnas.2301934120
  56. https://www.sciencedirect.com/science/article/pii/S0021925819646077
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC4250404/
  58. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.00125/full
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC3196764/
  60. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0022797
  61. https://doi.org/10.1186/gb-2006-7-9-236
  62. https://journals.biologists.com/jcs/article/115/3/455/34960/The-role-of-arrestins-in-the-termination-and
  63. https://doi.org/10.1073/pnas.96.7.3712
  64. https://doi.org/10.1021/bi900369c
  65. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2010.00705.x
  66. https://doi.org/10.1074/jbc.M806124200
  67. https://doi.org/10.1016/j.jmb.2022.167465
  68. https://doi.org/10.1126/science.aay1833
  69. https://www.nature.com/articles/s41467-025-62870-z
  70. https://www.cell.com/cell/fulltext/S0092-8674(17)30773-0
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC2562282/
  72. https://pubmed.ncbi.nlm.nih.gov/8505295/
  73. https://www.sciencedirect.com/science/article/pii/S0969212620302057
  74. https://www.jbc.org/article/S0021-9258(19)62972-8/pdf
  75. https://www.nature.com/articles/s41467-022-28152-8
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC8801586/
  77. https://europepmc.org/article/med/24292830
  78. https://pubmed.ncbi.nlm.nih.gov/9405462/
  79. https://pubmed.ncbi.nlm.nih.gov/11777907/
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC2903679/
  81. https://pmc.ncbi.nlm.nih.gov/articles/PMC3151035/
  82. https://pmc.ncbi.nlm.nih.gov/articles/PMC298705/
  83. https://pmc.ncbi.nlm.nih.gov/articles/PMC2839263/
  84. https://pmc.ncbi.nlm.nih.gov/articles/PMC517874/
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC9811579/
  86. https://www.pnas.org/doi/10.1073/pnas.0704849104
  87. https://www.embopress.org/doi/10.1038/s44319-024-00239-x
  88. https://pubmed.ncbi.nlm.nih.gov/9169442/
  89. https://www.pnas.org/doi/10.1073/pnas.1215176110
  90. https://pmc.ncbi.nlm.nih.gov/articles/PMC4521999/
  91. https://omim.org/entry/258100
  92. https://www.rcsb.org/structure/4ZWJ
  93. https://pubmed.ncbi.nlm.nih.gov/15634674/
  94. https://www.pnas.org/doi/10.1073/pnas.262789099
  95. https://www.pnas.org/doi/10.1073/pnas.0707936104
  96. https://www.nature.com/articles/s41467-022-34765-w
  97. https://www.sciencedirect.com/science/article/pii/S0021925819517884
  98. https://pubmed.ncbi.nlm.nih.gov/10521508/
  99. https://pmc.ncbi.nlm.nih.gov/articles/PMC7504914/
  100. https://pmc.ncbi.nlm.nih.gov/articles/PMC4429721/
  101. https://journals.biologists.com/jcs/article/126/19/4457/53835/arrestin-1-ARRDC1-and-arrestins-cooperate-to
  102. https://pubmed.ncbi.nlm.nih.gov/23886940/
  103. https://pubmed.ncbi.nlm.nih.gov/19815543/
  104. https://www.pnas.org/doi/10.1073/pnas.1208881109
  105. https://www.embopress.org/doi/10.15252/embr.202050437
  106. https://www.mdpi.com/1422-0067/21/14/4949
  107. https://www.cell.com/cell/pdf/S0092-8674%2816%2930910-2.pdf
  108. https://www.pnas.org/doi/10.1073/pnas.1712405114
  109. https://pmc.ncbi.nlm.nih.gov/articles/PMC9053844/
  110. https://www.nature.com/articles/ng0795-360
  111. https://pubmed.ncbi.nlm.nih.gov/9333241/
  112. https://www.cell.com/neuron/fulltext/S0896-6273(08)00528-X
  113. https://pubmed.ncbi.nlm.nih.gov/28459958/
  114. https://pmc.ncbi.nlm.nih.gov/articles/PMC9347377/
  115. https://pmc.ncbi.nlm.nih.gov/articles/PMC4396277/
  116. https://jnm.snmjournals.org/content/66/supplement_1/251073
  117. https://pubmed.ncbi.nlm.nih.gov/39763753/
  118. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.048723
Add your contribution
Related Hubs
User Avatar
No comments yet.